Stock VYNEVYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-03-17 pm EDT 		5-day change 1st Jan Change
1.870 USD +1.08% Intraday chart for VYNE Therapeutics Inc. -5.56% -44.18%
Mar. 17 Mindmed Appoints Matt Wiley as Chief Commercial Officer CI
Mar. 06 VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 CI

Highlights

Search
See the results
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024
Mar. 06
 CI
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Feb. 19
 CI
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo
Jan. 06
 CI
VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor
Dec. 23
 MT
VYNE Therapeutics Inc. Therapeutics Reports Positive Top-Line Phase 1A MAD Data for VYN202, Its Novel BD2-Selective Bet Inhibitor
Dec. 23
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $121,000
Nov. 07
 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 07
 CI
VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor
24-09-12
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $198,000
24-08-14
 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
24-08-14
 CI
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
24-06-13
 CI
Top Premarket Gainers
24-06-07
 MT
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
24-06-05
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000
24-05-09
 MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
24-05-09
 CI
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor
24-05-06
 CI
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
24-02-29
 CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
24-02-29
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000
24-02-29
 MT
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo
24-01-10
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000
23-11-13
 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-11-13
 CI
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
23-10-30
 CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000
23-08-14
 MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-14
 CI
19fc15a.xnRhHHsWutnCzh77SBzstLJCj7FTgK8IOmX2wZJ11Pk.qxEjST9giZiQ-W6-Ln7Z6_gTyOIE0ONRWRO7g8I-t7GDLVNLLFzNjKSMRw
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VYNE Stock
  4. News VYNE Therapeutics Inc.
  5. Highlights